Global Meningococcal Vaccines market report
it provides a vital recent industry data which covers in general market
situation along with future scenario for industry around the Globe. It also
consist of major data along with forecasts of a global market along with clear
presentation of diagrams.
Meningococcal vaccines are used to treat meningitis caused by
bacterium N. meningitidis. Previously there were no precautionary measures
available to avoid meningitis. Antibiotics along with nutrient supplements were
used to treat this disease after infection was confirmed. However, with the
advent of meningococcal vaccine, meningitis could be prevented. The global
market for vaccines was estimated to be $24 billion in 2013. The increasing
incidence of meningitis across the world is the major driving force for this
market. Rising awareness level of diseases and their vaccines also drives the
market for meningococcal vaccines. The maintenance of cold chain for the
delivery of vaccines leads to rise in cost of vaccination, which serves as the
major limiting factor for this market. World Health Organization is promoting
strategies for prevention of meningitis and is hoping to introduce this vaccine
in 26 countries of African region, which are suffering from meningitis and they
hope to achieve it by 2016. This would provide growth opportunities in this
market.
Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-toc-and-sample/330?utm_source=sy
Competitive Landscape
The major players in this market are Sanofi S.A., Novartis
International, GlaxoSmithKline, Pfizer Inc., Serum Institute of India Ltd.,
JN-International Medical Corporation, Nuron Biotech, Baxter International and
Biomed Pvt. Ltd. Novartis International with its new product is dominating the
market. It has come up with a new vaccine named Baxsero, which has proved to be
very beneficial in preventing meningitis. Pfizer Inc. is planning to target
adolescent with their vaccine.
High level analysis
The report analyses global meningococcal vaccines market with
the help of Porter’s five forces model. Porter’s model helps in analyzing the
market players, new entrants in the market and the strategies adopted by them.
In this market, the unavailability of substitutes result in high bargaining
power of suppliers and low bargaining power of buyers. The meningococcal
vaccine is a capital-intensive market; therefore, it is difficult for new
entrants to enter the business. Market dynamics is analyzed for the benefit of
the stakeholders.
Meningococcal vaccines types market analysis
The meningococcal vaccine market can be classified based on its
types into quadrivalent, bivalent, serogroup A, serogroup B and serogroup X.
Polysaccharide and conjugate are two types of quadrivalent vaccine. A new
vaccine named Baxsero, a conjugate vaccine has been a huge success in
prevention of meningitis.
Meningococcal vaccines geography market analysis
This market is classified based on its geography into North
America, Europe, Asia-Pacific and rest of the world (RoW). North American
market is the highest revenue generating region for this vaccine.
For More Information @ https://www.alliedmarketresearch.com/purchase-enquiry/330?utm_source=sy
No comments:
Post a Comment